ProPhase Labs Inc. has released a new investor presentation outlining recent corporate developments and strategic initiatives. The company is actively pursuing a sale or strategic partnership for its BE-Smart™ esophageal cancer diagnostic asset, with outreach to over 70 potential partners and acquirers in diagnostics, gastroenterology, oncology, pathology services, and precision medicine. ProPhase Labs expects to retain the capability to serve as the clinical testing laboratory for the assay, subject to definitive agreements. The presentation also details a proposed reverse merger with Advanced Biological Laboratories S.A. (ABL), under which ABL would become the majority owner of the combined company. The transaction is subject to due diligence, definitive agreements, regulatory approvals, and Nasdaq requirements. Additionally, the company is moving forward with a $50 million initiative through Crown Medical Collections, with net anticipated collections carved out exclusively for current ProPhase shareholders. You can access the full presentation through the link below. [Full Presentation](https://www.gnwp.com/en/news-release/2024/01/23/2814037/0/en/Pharmaloz-Manufacturing-Accelerates-Expansion-Improves-Pricing-Boosts-Profitability-and-Secures-New-Contracts.html)

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ProPhase Labs Inc. published the original content used to generate this news brief on February 05, 2026, and is solely responsible for the information contained therein.